ARCHIVES

Phase III Trial Data: Lenvatinib Extends PFS by Over 14 Months

This article is from The Cancer Letter archive.

Vol. 37 No. 6 | June 27, 2014

Download PDF Visit The Full Archive

Related Articles

ORI Final Findings Of Scientific Misconduct

September 16, 1994

In Brief: NCI Construction Authority To Continue Under Pane’s Plan: NCAB hearing In Philadelphia

March 11, 1988

The Cancer Letter Wins Investigative Reporting Award

June 8, 2001

Abstracts Of Papers From Copenhagen Leukemia Symposium

October 31, 1975

NIH Financial Plan Slated For Discussion At Dec. 18 Meeting

December 14, 1990

USC Scientists Says It’s Time Nobelists Recognize Value of Cancer Program

February 10, 1978